Epstein-Barr virus DNA quantification and follow-up in Tunisian nasopharyngeal carcinoma patients

Biomarkers

Volumn 16, Issue 3, 2011, Pages 274-280

  Hassen, Elham ^a   Farhat, Karim ^a,b   Gabbouj, Sallouha ^a   Bouaouina, Noureddine ^a,c   Abdelaziz, Hamdi ^d   Chouchane, Lotfi ^a,e  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^e WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

EBV DNA load; NPC; prognosis; survivals

Indexed keywords

ANTINEOPLASTIC AGENT; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CHILD; CONTROLLED STUDY; DNA DETERMINATION; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; DISEASE-FREE SURVIVAL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUNISIA; VIRAL LOAD; YOUNG ADULT;

HUMAN HERPESVIRUS 4;

EID: 79955117387     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.551409     Document Type: Article

References (18)

1. Bortolin MT, Pratesi C, Dolcetti R, Bidoli E, Vaccher E, Zanussi S, Tedeschi R, De Paoli P. (2006). Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undiferentiated carcinoma of nasopharyngeal type. Cancer Lett 233:247-254. (Pubitemid 43327380)
2. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. (2002). Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undiferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94:1614-1619. (Pubitemid 35378726)
3. Chang YS, Tyan YS, Liu ST, Tsai MS, Pao CC. (1990). Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplifcation. J Clin Microbiol 28:2398-2402. (Pubitemid 20353510)
4. Devi BC, Pisani P, Tang TS, Parkin DM. (2004). High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev 13:482-486. (Pubitemid 38737476)
5. Ferlay J, Bray F, Pisani P, Parkin DM. (2001). Globocan 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase no. 5. Lyon: IARC Press.
6. Kalpoe JS, Dekker PB, van Krieken JH, Baatenburg de Jong RJ, Kroes AC (2006). Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area. J Clin Pathol 59:537-541.
7. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. (2004). Quantifcation of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350:2461-2470. (Pubitemid 38736543)
8. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. (1999a). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59:1188-1191. (Pubitemid 29136244)
9. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. (1999b). Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59:5452-5455. (Pubitemid 29526455)
10. Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ. (2000a). Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60:6878-6881. (Pubitemid 32059157)
11. Lo YM, Leung SF, Chan LY, Chan AT, Lo KW, Johnson PJ, Huang DP. (2000b). Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 60:2351-2355. (Pubitemid 30262420)
12. Lo YM, Chan WY, Ng EK, Chan LY, Lai PB, Tam JS, Chung SC. (2001). Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 7:1856-1859. (Pubitemid 32994817)
13. Parkin DM, Whelan SL, Ferlay J, Teppo L, Tomas DB, Eds. (2002). Cancer Incidence in Five Continents. Volume VIII. Lyon: IARC Scientifc Publications No. 155.
14. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. (1985). Enzymatic amplifcation of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350-1354. (Pubitemid 16105164)
15. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Fachiroh J, Paramita DK, Tan IB, Haryana SM, Middeldorp JM. (2005). Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specifc viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 43: 3066-3073. (Pubitemid 40981304)
16. Tan EL, Selvaratnam G, Kananathan R, Sam CK. (2006). Quantifcation of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer 6:227.
17. Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS, Chao JY Liang KL, Chen KW, Wu CT, Lin JC (2010). Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 16:1016-1024.
18. Yu MC, Yuan JM. (2002). Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12:421-429. (Pubitemid 35370755)